PharmacyCodes



Valdecoxib [USAN] en es it fr

Valdecoxib [USAN] Brand names, Valdecoxib [USAN] Analogs

Valdecoxib [USAN] Brand Names Mixture

  • No information avaliable

Valdecoxib [USAN] Chemical_Formula

C16H14N2O3S

Valdecoxib [USAN] RX_link

http://www.rxlist.com/cgi/generic/bextra.htm

Valdecoxib [USAN] fda sheet

Valdecoxib_[USAN] FDA

Valdecoxib [USAN] msds (material safety sheet)

Valdecoxib [USAN] Synthesis Reference

No information avaliable

Valdecoxib [USAN] Molecular Weight

314.36 g/mol

Valdecoxib [USAN] Melting Point

No information avaliable

Valdecoxib [USAN] H2O Solubility

No information avaliable

Valdecoxib [USAN] State

Solid

Valdecoxib [USAN] LogP

3.003

Valdecoxib [USAN] Dosage Forms

Tablet

Valdecoxib [USAN] Indication

For the treatment of osteoarthritis and dysmenorrhoea

Valdecoxib [USAN] Pharmacology

Valdecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is classified as a nonsteroidal anti-inflammatory drug (NSAID). Valdecoxib is used for its anti-inflammatory, analgesic, and antipyretic activities in the management of osteoarthritis (OA) and for the treatment of dysmenorrhea or acute pain. Unlike celecoxib, valdecoxib lacks a sulfonamide chain and does not require CYP450 enzymes for metabolism.

Valdecoxib [USAN] Absorption

No information avaliable

Valdecoxib [USAN] side effects and Toxicity

No information avaliable

Valdecoxib [USAN] Patient Information

BEXTRA can cause GI discomfort and, rarely, more serious GI side effects, which may result in hospitalization and even fatal outcomes. Although serious GI tract ulcerations and bleeding can occur without warning symptoms, patients should be alert for the signs and symptoms of ulcerations and bleeding, and should ask for medical advice when observing any indicative sign or symptoms. Patients should be apprised of the importance of this follow-up Effects ó Risk of GI Ulceration, Bleeding, and Perforation).

Patients should report to their physicians, signs or symptoms of gastrointestinal ulceration or bleeding, skin rash, weight gain, or edema.

Patients should be informed of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, pruritus, jaundice, right upper quadrant tenderness, and flu-like symptoms). If these occur, patients should be instructed to stop therapy and seek immediate medical attention.

Patients should also be instructed to seek immediate emergency help in the case of an anaphylactoid reaction.

In late pregnancy, BEXTRA should be avoided because it may cause premature closure of the ductus arteriosus.

Valdecoxib [USAN] Organisms Affected

Humans and other mammals